Oric Pharmaceuticals, INC 8-K filings

ORIC Pharmaceuticals reported Q2 2026 results, highlighting the initiation of a global Phase 3 trial for rinzimetostat in prostate cancer and a cash runway extending into late 2028.

ORIC Pharmaceuticals, Inc. has amended its 2022 Inducement Equity Incentive Plan to increase the number of shares available for issuance.

ORIC Pharmaceuticals announced first quarter 2026 financial results, highlighting progress in its rinzimetostat and enozertinib clinical programs and a strong cash position extending runway into late 2028.

ORIC Pharmaceuticals, Inc. announced the launch of a new $200 million at-the-market equity offering program, following the sale of $139.7 million under its previous program.

ORIC Pharmaceuticals announced positive Phase 1b data for rinzimetostat and enozertinib, alongside a significantly extended cash runway into the second half of 2028.

ORIC Pharmaceuticals presented positive Phase 1b data for enozertinib (ORIC-114) in EGFR-mutated NSCLC, demonstrating strong systemic and CNS activity.

ORIC Pharmaceuticals reports updated Phase 1b data for ORIC-944, demonstrating strong clinical activity and a favorable safety profile in metastatic castration-resistant prostate cancer patients.

ORIC Pharmaceuticals reported positive Phase 1b data for ORIC-944 in prostate cancer, extended its cash runway into 2H 2028, and announced key leadership and clinical milestones.

ORIC Pharmaceuticals announced Q2 2025 financial results, a strategic pipeline prioritization leading to a 20% workforce reduction, and an extended cash runway into 2H 2028 following recent financings.

ORIC Pharmaceuticals, Inc. successfully held its annual meeting of stockholders on June 11, 2025, with shareholders electing two Class II directors and ratifying KPMG LLP as its independent registered public accounting firm.

ORIC Pharmaceuticals announced a $125 million private placement financing and released positive preliminary Phase 1b clinical trial data for ORIC-944 in metastatic castration-resistant prostate cancer, extending its cash runway into the second half of 2027.

ORIC Pharmaceuticals reports its Q1 2025 financial results, highlighting progress in clinical development plans, extended cash runway into 2027, and key corporate milestones.

ORIC Pharmaceuticals increases the number of shares reserved for issuance under its 2022 Inducement Equity Incentive Plan by 1,100,000 shares, bringing the total to 2,250,000.

ORIC Pharmaceuticals announces a refined clinical development strategy for its lead programs, ORIC-944 and ORIC-114, extending its cash runway into 2027.

ORIC Pharmaceuticals reports financial results for Q4 and full year 2024, highlighting clinical trial progress, strategic collaborations, and a cash runway into late 2026.

ORIC Pharmaceuticals highlighted its progress with ORIC-114 and ORIC-944, aiming for pivotal studies in 2025 and 2026, respectively, while also showcasing a strong financial position.

ORIC Pharmaceuticals announced its third quarter 2024 financial results, highlighting progress in clinical trials and preclinical data for its oncology drug candidates.

ORIC Pharmaceuticals reported its second quarter 2024 financial results, highlighted by clinical trial advancements and strategic collaborations.

ORIC Pharmaceuticals held its annual meeting on June 12, 2024, electing two Class I directors and ratifying the appointment of KPMG LLP as its independent auditor.

ORIC Pharmaceuticals announced its first quarter 2024 financial results and provided updates on its clinical programs, including progress with ORIC-114 and ORIC-944.

ORIC Pharmaceuticals has increased the number of shares reserved for issuance under its 2022 Inducement Equity Incentive Plan by 650,000, bringing the total to 1,150,000 shares.

ORIC Pharmaceuticals reported positive initial data from three clinical programs and secured $210 million in private financing, extending their cash runway into late 2026.

ORIC Pharmaceuticals has successfully raised approximately $125 million through a private placement to fund its clinical-stage oncology programs and for general corporate purposes.